MPI : Fly Fishing, Photography & Solving Cancer…Same Same but Different!



Company News

Hoersholm; January 19th 2016 – Congratulations to our very own talented CTO, Thomas Jensen! He will be speaking at TEDxBozeman 2016 that will be held on Saturday April 9th, 2016 in Bozeman, Montana USA.

Meet Thomas!
Thomas serves as our CTO at Medical Prognosis Institute and Oncology Venture. He is pioneering the bridging of good science, effective laboratory techniques, and bioinformatics to advance the biology of cancer. He founded and leads the Medical Prognosis Institute’s -MPI laboratories in Denmark and in the USA. Amongst Thomas’ accolades are his inventions of molecular biological guidelines and techniques for high-quality RNA processing. This allows for high-resolution analysis of cancer patients’ biopsies. His inventions are an important foundation of MPI’s Drug Response Predictor platform – a high-resolution bioinformatics tool that predicts the sensitivity and resistance of anticancer drugs.

Bozeman, Montana is Thomas’ sanctuary where he enters his mental laboratory to hear himself think, and concoct big ideas to help solve one of the 21st century’s biggest problem -cancer.

He basks in Bozeman’s natural serenity equipped with fly rods and cameras, same same but different from his daily work tool at the lab. Montana is where he has discovered the remarkable parallels between the art and science of: fly fishing, photography and cancer solving.

DRP® used by MPI and OV
Medical Prognosis Institute -MPI was founded in 2004 based on a cutting edge technology where data from cell line assays were translated into important information for the treatment of cancer patients. This Drug Response Predictor technology – DRP® is today used by MPI for development of personalized medicine for cancer patients and by Oncology Venture for changing the odds of anti-cancer drugs under development as patients are screened for likelihood of sensitivity before treated with the drug under development.

What is TEDx?
In the spirit of ideas worth spreading, TED has created a program called TEDx. TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. Our event is called TEDxBozeman, where x = independently organized TED event. At our TEDxBozeman event, TEDTalks video and live speakers will combine to spark deep discussion and connection in a small group.

If you are in the Bozeman neck of the woods on April 9th, come see Thomas Jensen along with a roster of interesting speakers inspire the TEDxBozeman 2016 theme of “Confluence.”

Link to TEDxBozeman speakers 2016: http://www.tedxbozeman.com/speakers/

For further information, please contact
Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Cell Phone: +45 21 60 89 22
http://www.medical-prognosis.com

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.